Worldwide trends and research & development in cervical dystonia management market

Cervical dystonia, also known as spasmodic torticollis, rare neurological disorder that originates in the brain. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head. The severity of cervical dystonia can vary, but the disorder can cause significant pain and discomfort as well as difficulty due to the abnormal postures. It can affect the quality of life and activities of daily living including employment. Cervical dystonia typically begins in middle age, and rarely begins in adolescence and young adulthood. The cause of cervical dystonia is unknown, although a genetic susceptibility is thought to underlie some cases.

 Request Sample Report:

https://precisionbusinessinsights.com/request-sample?product_id=15957

The major driving factors for the global cervical dystonia management market is increase in aging population across the globe. Females are more likely to be get affected by cervical dystonia. Besides this increase in treatment for cervical dystonia and improvement in infrastructure provided fuel for the growth of the market. Furthermore, low and increase in cost of treatment is the major cause for restraining the growth of Botulinum Toxin (BNT) market.

The global cervical dystonia management market is categorized as under- 

1. Route of administration

• Oral
• Intravenous

1. Drug class

• Dopaminergic drugs
• Anti-cholinergic drugs
• GABA Agonists
• Anti-Convulsants

1. End- users

Hospital, retail pharmacies and others.

And lastly on the basis of geographical region, the Botulinum toxin (BNT) market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominates the Botulinum toxin therapy market due to developed infrastructure, governmental initiatives, and increase in demand for the better treatment of cervical dystonia driving factor. Furthermore, increase in aging population in Canada fueling the growth of North America Botulinum toxin therapy market. Europe and Asia-Pacific accounts to have significant market share. However, Asia-Pacific expected to dominate the market in the forecast period due to continuous development and increase in cervical dystonia treatment procedures. Furthermore, large patient pool in Asia-Pacific region contributes significant growth for Botulinum toxin market.

Some of the key players in Botulinum toxin market are ALLERGAN (Ireland), US WorldMeds (U.S.), Ipsen (France), Addex Therapeutics (Switzerland), and Revance Therapeutics Inc. (U.S.). In March, 2017, Ipsen Biopharmaceuticals Inc., the Canadian affiliate of Ipsen has received Health Canada approval for DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) to treat cervical dystonia.

 For More Information :https://precisionbusinessinsights.com/market-reports/global-cervical-dystonia-management-market/